CWM
MRNA icon

C2C Wealth Management’s Moderna MRNA Stock Holding History

C2C Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,520
Closed -$567K – 183
2023
Q3 		$567K Sell
5,520
-6,899
-56% -$770K 0.08% 128
2023
Q2 		$1.52M Sell
12,419
-3,158
-20% -$421K 0.2% 56
2023
Q1 		$2.42M Buy
15,577
+4,567
+41% +$753K 0.39% 28
2022
Q4 		$2.12M Sell
11,010
-431
-4% -$70.5K 0.37% 28
2022
Q3 		$1.44M Sell
11,441
-300
-3% -$45.5K 0.28% 39
2022
Q2 		$1.96M Buy
11,741
+1,800
+18% +$257K 0.36% 33
2022
Q1 		$1.49M Sell
9,941
-2,265
-19% -$381K 0.25% 50
2021
Q4 		$3.1M Buy
+12,206
New +$3.57M 0.45% 26

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

C2C Wealth Management's MRNA Position: Q4 2023 in Review

C2C Wealth Management sold out of Moderna (MRNA) in Q4 2023, closing a stake of 5,520 shares — an estimated $567K sold.

C2C Wealth Management first reported a position in MRNA in Q4 2021 and held it in 8 quarters. The position peaked at $3.1M in Q4 2021. 885 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • C2C Wealth Management reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • C2C Wealth Management sold 5,520 Moderna shares in Q4 2023, an estimated $567K.
  • C2C Wealth Management first reported a position in Moderna in Q4 2021 and held it in 8 quarters.
  • C2C Wealth Management's Moderna position peaked at $3.1M in Q4 2021.
  • 885 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on C2C Wealth Management's 13F filing for Q4 2023, filed 13 Feb 2024.